The CINP-AsCNP 2025 Joint Congress marks the return of the World Congress of Neuropsychopharmacology to Australia after nearly three decades. Scheduled from 15–18 June 2025 at the Melbourne Convention and Exhibition Centre, the congress will convene experts from research institutions, regulatory authorities, and the pharmaceutical industry to discuss advancements in neuropsychopharmacology.
The theme “Advancing Intelligent Horizons Towards Brain Health” reflects a commitment to exploring innovative approaches to mental health treatment and research, integrating the latest findings in neuroscience, psychiatry, and pharmacology to improve patient outcomes worldwide.
Key Features of the Show
- Plenary Lectures: Five keynote sessions delivered by world-renowned researchers covering cutting-edge developments in neuropsychopharmacology.
- Symposia: Eighteen sessions featuring expert speakers discussing the latest breakthroughs in psychiatric treatments, neuroscience, and drug development.
- Interactive Sessions: New session formats such as Featured Communications, Meet the Experts, Campfire Sessions, Spotlight Sessions, and Data Blitz to enhance engagement and knowledge sharing.
- Networking Opportunities: Extensive social events, industry networking sessions, and collaborative discussions with peers and key opinion leaders.
Who Should Exhibit?
The congress provides an excellent platform for organisations involved in:
- Pharmaceuticals: Companies developing neuropsychiatric drugs and treatments.
- Medical Devices: Manufacturers of technologies related to mental health diagnostics and therapies.
- Research Institutions: Universities and organisations conducting neuroscience and pharmacology research.
- Publishing Houses: Publishers of scientific journals and literature in psychiatry, neuroscience, and pharmacology.
- Professional Associations: Societies and organisations supporting brain health research and education.
Exhibitors will have the opportunity to connect with a global audience of professionals dedicated to advancing brain health research and treatment.
Who Attends?
The congress attracts a diverse group of professionals, including:
- Psychiatrists and Psychologists: Clinicians involved in diagnosing and treating mental health disorders.
- Neuroscientists: Researchers studying brain function, neuroplasticity, and psychiatric disorders.
- Pharmacologists: Experts in the development and testing of psychiatric medications.
- Clinical Researchers: Professionals conducting clinical trials and neuropharmacology studies.
- Regulatory Professionals: Authorities involved in drug approval and policy-making.
- Students and Early Career Researchers: Young professionals looking to expand their knowledge and network within the field.
Attendees will benefit from high-quality scientific content, interactive sessions, and networking opportunities with global leaders in neuropsychopharmacology.
Why Should You Exhibit?
- Showcase Innovations: Present your latest research, products, and services to a highly engaged audience.
- Connect with Decision-Makers: Network with industry leaders, researchers, and clinicians.
- Enhance Brand Visibility: Gain recognition among key stakeholders in neuropsychopharmacology.
- Generate Business Leads: Build relationships with potential clients and collaborators.
- Contribute to Scientific Advancement: Support the development of new treatments and discoveries in brain health.
Key Stats from the Last Show
- Attendees: Over 1,500 professionals participated in the previous congress.
- Speakers: More than 60 experts delivered impactful sessions and lectures.
- Exhibitors: Leading organisations showcased advancements in neuroscience and psychiatry.
- Networking Events: Numerous structured and informal opportunities facilitated global collaboration.
